Skip to main
  1. Stocks
  2. Viatris
  3. Forecast
VTRS

Viatris (VTRS) Stock Forecast & Price Target

Viatris (VTRS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Viatris is viewed favorably because the Pacira acquisition expands its U.S. branded pain franchise, adds roughly 340 FTEs of commercial infrastructure, and strengthens launch execution for fast-acting meloxicam ahead of the Dec. 27 PDUFA. The deal also improves the margin profile, with Pacira’s ~80% gross margin, while supporting forecasts of 2027 revenue of $15.75B and EBITDA of $5.04B, alongside about $50M in annual savings by YE28. More broadly, the market may be underestimating Viatris’s improving growth mix from generics, biosimilars, legacy brands, and pipeline assets such as fast-acting meloxicam, selatogrel, and cenerimod, which could support a rerating as execution improves.

Bears say

Viatris is viewed negatively because its core business remains heavily exposed to commoditized generics, volume-based procurement in Greater China, and structural price reductions in JANZ, all of which can pressure revenue and margins. Its growth depends on execution around new products and pipeline assets, yet commercial uptake for launches like Journavx may be constrained by payer access, reimbursement friction, and hospital budget resistance, while manufacturing compliance issues at Indore or Nashik could further disrupt supply and raise costs. The pipeline also carries meaningful binary risk, as Selatogrel underpins a $1Bn-plus peak sales estimate, Cenerimod already missed a Phase 2b primary endpoint, and acquisition or integration risk around PCRX adds another layer of uncertainty.

Viatris (VTRS) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viatris and is not a guaranteed prediction by Public.com or investment advice.

Viatris (VTRS) Analyst Forecast & Price Prediction

Get the latest Viatris (VTRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Viatris (VTRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viatris (VTRS) Forecast

Analysts have given Viatris (VTRS) a Buy based on their latest research and market trends.

According to 8 analysts, Viatris (VTRS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viatris (VTRS)


Viatris (VTRS) Analyst Forecast & Price Prediction

Get the latest Viatris (VTRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Viatris (VTRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VTRS stock data and trends